Realm Therapeutics

www.realmtx.com TICKER: RLM     EXCHANGE: AIM

Realm Therapeutics is an emerging specialty bio-pharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary hypochlorous acid-based technology. 

LATEST REPORTS

 
Moving to the timelines
Published: Mar 23 2017

Realm Therapeutics (RLM) reports alongside FY16 financial results that its clinical pipeline is advancing to plan. RLM also confirms that both of its lead candidates - PR022, a novel high concentration formulation of hypochlorous acid (HOCl) to treat Atopic Dermatitis (AD) and PR013 to treat Allergic Conjunctivitis (AC) - will move into Phase II studies in 2017. Consequently, top line data readouts for both candidates is anticipated during H118.The novel topical treatments aim to provide efficacious and safer alternatives to standard treatments in both indications providing significant commerc

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Leapfrogging Phase I in Atopic Dermatitis
Published: Mar 01 2017

Realm Therapeutics (RLM), based in Malvern PA, is an emerging specialty biopharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary hypochlorous acid based technology. RLM (formerly PuriCore before a name change in December 2016) emerges as a focused entity having divested its non-strategic supermarket retail business for $13.5m gross. RLM is advancing its pipeline to plan having received FDA approval to take its lead candidate PR022 a novel high concentration formulation of hypochlorous acid (HOCl), into Phase II s

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
Realm Therapeutics plc - Equity Development Investor Forum, January 2017
Published: Jan 27 2017

Alex Martin, Chief Executive Officer, explains the strategy behind Realm Therapeutics.

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

 
A New Realm of Opportunity
Published: Jan 19 2017

Realm Therapeutics (RLM) is an emerging specialty bio-pharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary hypochlorous acid-based technology. RLM (formerly PuriCore plc) is now a focused entity, having divested its non-strategic supermarket retail business for $13.5m to Chemstar Corp in October 2016.RLM is preparing to take its pipeline of novel pharmaceutical therapies, which hinges on patented high concentration formulations of hypochlorous acid, into Phase II studies during 2017. RLM will tackle unmet need fo

REGISTER / LOGIN TO VIEW THIS RESEARCH IN FULL

ARCHIVE